Biocon, Mylan win US court ruling in favour of insulin Glargine
Posted by
www.biotecnika.org
US District Court of New Jersey found the device patent claims (US
Patent No. 9526844) asserted by Sanofi against Biocon and Mylan's
insulin Glargine product 'not infringed' and 'invalid' for lack of
written description, said Biocon in a press statement. Semglee is
co-developed with Mylan in the US.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biocon-mylan-win-us-court-ruling-that-nullifies-sanofis-patent/articleshow/74580213.cms
Subscribe to:
Post Comments (Atom)
Post a Comment